文献速递淋巴瘤

一线利妥昔单抗维持治疗改善滤泡性淋巴瘤患者结局:一项北欧协作研究

Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study.
PubMed 文献 · Blood Adv · 2018-01-01

该研究利用两个独立的人群队列,评估一线利妥昔单抗维持治疗(MR)对完成R-chemo诱导后滤泡性淋巴瘤患者时间相关终点及组织学转化风险的影响。训练队列733例丹麦患者中364例接受MR,MR组5年总生存(89% vs 81%;P=.001)和无进展生存(72% vs 60%;P<.001)均改善,且与组织学转化风险降低相关(P=.049)。验证队列190例芬兰患者证实MR对5年OS(89% vs 81%;P=.046)和PFS(70% vs 57%;P=.005)的有利影响,但未发现组织学转化风险降低。

要点

  • 训练队列中MR组5年OS为89% vs 未接受MR组81%(P=.001),5年PFS为72% vs 60%(P<.001)。
  • 训练队列中MR与组织学转化风险降低相关(P=.049),验证队列未发现该风险降低。
  • 验证队列中MR组5年OS为89% vs 81%(P=.046),5年PFS为70% vs 57%(P=.005)。

核心结论

  • 基于人群的数据提示,R-chemo后以MR巩固可改善滤泡性淋巴瘤患者的结局。

研究设计与样本

  • 研究使用两个独立的人群队列,训练队列为733例丹麦患者,验证队列为190例芬兰患者。
  • 纳入标准为:完成一线R-chemo诱导治疗、诱导后存活且适合MR、此时无组织学转化证据。
  • 训练队列中364例接受MR巩固,369例未接受MR。

主要发现

  • 训练队列中接受MR的患者更多具有晚期临床分期(90% vs 78%)、高FLIPI评分(64% vs 55%)和骨髓浸润(49% vs 40%)。
  • 训练队列中MR组5年OS为89% vs 未接受MR组81%(P=.001),5年PFS为72% vs 60%(P<.001)。
  • 训练队列中MR与组织学转化风险降低相关(P=.049)。
  • 验证队列中MR组5年OS为89% vs 81%(P=.046),5年PFS为70% vs 57%(P=.005),但未发现组织学转化风险降低。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The introduction of the anti-CD20 antibody rituximab in combination with chemotherapy (R-chemo) has improved the prognosis of patients with follicular lymphoma (FL). During the last decade, the addition of a maintenance treatment with rituximab (MR) after R-chemo has been tested with the hope of further improving the outcome of these patients. Using 2 independent population-based cohorts, we investigated the effect of up-front MR on time related end points as well as the risk of histological transformation (HT). FL patients were included if they: (1) completed first-line induction treatment with R-chemo, (2) were alive after induction treatment and eligible for MR, and (3) had no evidence of HT at this time point. The training cohort consisted of 733 Danish patients of whom 364 were consolidated with MR; 369 were not. Patients receiving MR more often had advanced clinical stage (90% vs 78%), high Follicular Lymphoma International Prognostic Index (FLIPI) score (64% vs 55%), and bone marrow infiltration (49% vs 40%). Those consolidated with MR had an improved 5-year overall survival (OS; 89% vs 81%; P = .001) and progression-free survival (PFS; 72% vs 60%; P < .001). In the training cohort, MR was associated with a reduction of HT risk (P = .049). Analyses of an independent validation cohort of 190 Finnish patients confirmed the favorable impact of MR on 5-year OS (89% vs 81%; P = .046) and PFS (70% vs 57%; P = .005) but did not find a reduced risk of HT. The present population-based data suggest that the outcome of patients with FL has improved after consolidation of R-chemo with MR.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Madsen C, Clausen MR, Plesner TL, et al. Up-front rituximab maintenance improves outcome in patients with follicular lymphoma: a collaborative Nordic study. Blood Adv. 2018. PMID: 29976619. doi:10.1182/bloodadvances.2018017673

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。